Core Viewpoint - The article discusses the rapid growth of the dental implant market and highlights the innovative dental implant distractor developed by Shanghai Yangshan Biotechnology Co., which aims to address the challenges of bone deficiency in dental implant surgeries [3][9]. R&D Background - The dental implant market is experiencing significant growth due to increased awareness of oral health and the popularity of implant technology. However, the success rate of implant surgeries is influenced by various factors, particularly the condition of the alveolar bone [3]. - Many patients face issues such as alveolar bone atrophy or insufficient bone volume before surgery, complicating the procedure. Traditional methods like bone grafting and guided bone regeneration (GBR) have limitations, including complexity, trauma, and prolonged recovery time [3]. Traction Osteogenesis Technology - Traction osteogenesis technology is emerging as a new method for bone augmentation, offering advantages such as no donor site requirement and minimal impact on surrounding soft tissues. This technique promotes new bone formation through applied traction, improving conditions for dental implant surgeries [5]. - The integration of digital technologies like 3D printing and CAD/CAM has significantly enhanced the precision and predictability of dental implant procedures, aligning with the development of the dental implant distractor [5]. Clinical Application - Clinical results indicate that traction osteogenesis can increase alveolar bone volume, providing better conditions for implant placement. Additionally, this technology reduces postoperative bone resorption and complications such as bone window and fracture [8]. Market Overview - The global dental implant market was approximately $5 billion in 2023 and is projected to reach $7 billion by 2028, with a CAGR of about 7%. Bone traction osteogenesis devices account for 10-15% of the dental implant market [11]. - In Europe and the U.S. (Switzerland, the U.S., Germany), there is a technological advantage in the design of distractors and digital implant solutions, holding over 90% market share. In Asia (South Korea, Japan), products are noted for their cost-effectiveness and regional adaptability [11]. - The Chinese dental implant market is expected to reach RMB 15-20 billion in 2024, with a CAGR of approximately 10-12%. The number of dental implant surgeries is increasing annually, with around 2 million implants performed in 2023. About 30-40% of patients require bone augmentation due to insufficient alveolar bone, with traction osteogenesis technology's market penetration expected to grow at a CAGR of 15% from 2025 to 2030 [11]. Competitors in the Same Field - Domestic competitors include WEGO, which offers dental implant systems and bone augmentation devices, and Kangsheng Medical, which is developing implant systems and bone augmentation tools [12][15]. - International competitors include Nobel Biocare (Sweden) and CORTEX (Israel), both of which provide dental implants and traction osteogenesis devices, emphasizing advanced design and integration with digital workflows [17][18]. About Yangshan Biotechnology - Shanghai Yangshan Biotechnology Co., established in September 2023, is located in Minhang District, Shanghai. The company has formed partnerships with top-tier hospitals and well-known dental clinic chains. Its core product has received a national scientific advancement award, and the core team consists of experienced professionals in surgical robotics and oral-maxillofacial devices [19].

Group 1: Company Growth and Market Strategy - The company aims to enhance its industry position through technological innovation and digital transformation in the dental sector, focusing on external growth opportunities via investments and acquisitions [1] - The long-term outlook for the dental digital equipment business is positive, driven by factors such as aging population, rising economic levels, and increased awareness of oral care, indicating a broad market potential [2] Group 2: Revenue and Market Distribution - In the first half of 2024, domestic revenue accounted for 41.22%, highlighting the significant growth potential and policy support in the Chinese market, which serves as a foundation for global expansion [3] - The company has a balanced distribution of sales across over 100 countries and regions, including Europe, North America, Asia, South America, and Australia, which helps mitigate risks associated with reliance on a single market [3] Group 3: Production and Operational Preparedness - The company has established a production base in South Korea after acquiring a controlling stake in a local firm, primarily for the production of implant systems [4] - Ongoing automation upgrades in production lines are aimed at ensuring stable product supply and manageable operational costs for overseas production bases [4]